Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Acute Care of COPD: Gaps in our knowledgeRobert A. Wise, M.D.
May 20, 2010
Outline of talk
• Importance of COPD exacerbations• Current treatments• Areas for improvement• Significant knowledge gaps• Strategies for improving care
Importance of COPD exacerbations
20%-24%
5%-10%
22%-32%
13%-33%
Hospital mortality
Hospital mortality
Relapse (repeat ER visit)
Treatment failure rate
In hospitalized patients
In ER patients
In ICU patients
In outpatients
Outcome of Exacerbations – Room for Improvement
• Seneff et al. JAMA. 1995; 274:1852-1857; Murata et al. Ann Emerg Med. 1991;20:125-129; Adams et al. Chest. 2000;117:1345-1352.
Exacerbations Affect Quality of Life
Seemungal TA, et al. Am J Respir Crit Care Med. 2000;161:1608–1613.
* P<0.05 versus lower exacerbation rate
49 5164
34
6272
79
48
0102030405060708090
100
Total SymptomsActivities
Activities Impacts
SGR
Q S
core
0-2 Exacerbations 3-8 Exacerbations
*
**
*
Baseline Rate of Change in SGRQ (control group)and Exacerbation Frequency During the UPLIFT Trial
0
0.5
1
1.5
2
2.5
Rat
e of
cha
nge
in S
GR
Q to
tal s
core
(uni
ts/y
r)
0 >0 to 1 >1 to 2 >2
SGRQ, St George’s Respiratory Questionnaire
Exacerbation Rate (per patient-year)
High Mortality Following Emergency Department Visit for COPD Exacerbation
Kim S, et al. COPD. 2006;3:75-81.
5%9% 11%
16%
23%
32%
39%
0%5%
10%15%20%25%30%35%40%45%
30 Days 60 Days 90 Days 180Days
1 Year 2 Years 3 Years
Time Following Visit
Perc
ent M
orta
lity
7
Effects of Repeated Exacerbations on Survival
Time (months)
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40 50 60
Pro
babi
lity
of s
urvi
ving
p<0.001
p=0.07
3-4 exacerbations
1-2 exacerbations
No exacerbationProspective study
Cohort of 304 males
Exacerbations requiringhospital treatmentduring the year
Follow-up over 5 years
Soler-Cataluña JJ et al. Thorax 2005;64:925-31
2010 projected Health Care Costs for COPD
Hospital Care, $13.2
Physican Fees, $5.5
Prescriptions, $5.8
Home Health Care, $1.3
Long-term Care, $3.7
Hospital Care Physican Fees PrescriptionsHome Health Care Long-term Care
.
Cost in BillionsTotal = $29.5
Recurrence of Exacerbations
• 27% of first exacerbations associated with second exacerbation in 8 weeks
• 34% of 1,221 hospitalized patients in UK readmitted within 3 months (range 5-65%)
C M Roberts et al.Thorax 2002;57:137–141Hurst et al. Am J Respir Crit Care Med 2009; 179:369
Effects of Repeated Exacerbations on Recovery of QoL
•6-month prospective study
•After one exacerbation treated with antibiotics
•Followed for 26 weeks.
•31% had recurrent exacerbation
•N =Patients remaining in the study at that time point
No new exacerbation
With a further exacerbation
N=133
SGR
Q to
tal s
core
N=133
N=221N=233
N=280
N=116N=115
N=299
30
40
50
60
Presentation 4 weeks 12 weeks 26 weeks
• Spencer S. et al. Thorax 2003;58:589
Recurrent admissions after hospital discharge –the critical issue for COPD in 2010
• 10% of patients account for 70% of costs• Medicare reimbursement schedule makes
hospitals interested• High mortality in frequent exacerbators• Wide range of readmissions at hospitals (5-65%)• Event rate high enough to study easily• Outcome measure easy to count• We can probably do something about it
Triple therapy – Fewer hospitalizations
Tiotropium (n=156)
Tiotropium + Salmeterol
(n=148)
Tiotropium + Salmeterol + Fluticasone
(n=145)% Pts with 1 or
more exacerbation(s)
62.8 % 64.8% 60.0%
Total Exacerbations 222 226 188
Exacerbations with Hosp
49 38 26*
Aaron et. al. Ann Int Med. 2007
Checklist for Acute Coronary Syndrome Discharge
ASA ACE / ARBBeta-blockerStatinRehabilitation / Exercise prescriptionSmoking cessation treatment / adjunctsHypertension treated
Checklist for AE-COPD Discharge
Has he got a way to get home?
Checklist for AE-COPD Discharge
ICS / LABALAMAInhaler instruction with actual devicesOxygen instructionSteroid taper instruction and monitoringRehabilitation / Exercise prescriptionSelf-management care planFollow-up care planDrug affordability
Need for economic analyses?
Cost-Utility Analyses - TORCH• Salmeterol-Fluticasone $33,865 / QALY• Salmeterol alone $20,792 / QALY• Fluticasone – null
• Salmeterol-Fluticasone $52,046 / QALY• Salmeterol alone $56,519 / QALY
• Salmeterol-Fluticasone $43,600 / QALY• Salmeterol alone $197,000 / QALY
Earnshaw et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir Med. 2009 Jan;103(1):12-21.Oba Y.et al. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care. 2009;15:226-32Briggs A et al. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. Eur Respir J. 2010;35:532-9
Etiology of Exacerbations of COPD
• Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11
e.g., air pollution. climate change, noncompliance,etc.
Bacteria
Bacteria and virus
Virus
Non-infectious
Immunization
• Influenza vaccination• Pneumococcal vaccination
Pneumococcal Vaccine Dec-March
0.59 0.53
1
1.68
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
I+/P- I+/P+ I-/P- I-/P+Vaccination status
Rel
ativ
e R
isk
of D
eath
P = Pneumococcal vaccineI = Influenza vaccinen = 177,120
Adjusted for age, gender,Co-morbidities
**
*
Schembri S. et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64:567-72.
Pneumococcal Vaccine Apr-Nov
0.980.88
1
1.29
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
I+/P- I+/P+ I-/P- I-/P+Vaccination status
Rel
ativ
e R
isk
of D
eath
P = Pneumococcal vaccineI = Influenza vaccinen = 177,120
Adjusted for age, gender,Co-morbidities
*
Schembri S. et al. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64:567-72.
Key questions
• Is it harmful to give pneumococcal vaccine?
• Is it beneficial to give influenza vaccine for hospitalized COPD patients on steroids?
Helium-Oxygen Mixtures
• Improves exercise tolerance and dynamic hyperinflation in COPD
• Does not improve bronchodilator response as carrier for nebulizer
• Question: Can Heliox by inhalation or by NIPPV prevent intubation or improve outcomes compared with NIPPV alone?
Rodrigo G, Pollack C, Rodrigo C, Rowe B. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(2):CD003571.
Heliox and PPV reduces work of breathing during COPD exacerbations
Jaber S, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1191-200
Heliox and PPV decrease PaCO2 during COPD exacerbations
Jaber S, et al. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1191-200
Self – Management / Case ManagementCan’t hurt, can it?
Self Management – Cochrane Systematic Review
• … because of heterogeneity in interventions, study populations, follow-up time, and outcome measures, data are still insufficient to formulate clear recommendations regarding the form and contents of self-management education programmes in COPD. There is an evident need for more large RCTs with a long-term follow-up, before more conclusions can be drawn.
Effing et al. Self-Management education for patients with COPD. Cochrane Review 2007 4:CD002990
Care Management in COPD
N = 743 ptsUsual Care vs Disease Management•1.5 hr education•Action plan for self treatment•Monthly f/u calls from case manager•Results: All cause hospitalizations decreased 28%
Rice KL, Disease Management Program for Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Am J Respir Crit Care Med. 2010 Jan 21. Epub.
Mucolytics
• Meta-analysis of 28 trials with 7,042 pts.– 21% reduction in exacerbation rate– 44% reduction in days of disability– 1.93 OR of remaining exacerbation free– Possibly increased benefit in patients NOT on
ICS
Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Reviews 2010, CD001287.
Carbocysteine – PEACE Trial
Zheng JP. . Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371::2013-8
•Carbocysteine - 1.01 exac/yr
•Placebo – 1.35 exac/yr
•P = 0.004
•No effect for 3 months
•No interaction with ICS, smoking status
Corticosteroids for COPD exacerbation in hospital
Niewoehner DE, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. VA Study Group. N Engl J Med. 1999;340:1941-7
Hospital daysDecreased from9.7 to 8.5 in steroid group
Oral steroids after ER visit for COPD
Aaron SD, et al.. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618-25
Steroid Resistance in COPD
• Induced by oxidative / nitrosative stress on HDAC2
• Reduced by theophylline, anti-oxidant treatments
• Can adjuvants be used to augment corticosteroid efficacy?
Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004 6;200:689-95
Etiology of Exacerbations of COPD
Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11
e.g., air pollution. climate change, noncompliance,etc.
Bacteria
Bacteria and virus
Virus
Non-infectious
Inhalation during swallowing in COPD
0%
2%
4%
6%
8%
10%
12%
14%
Cookie Pudding
COPD Control
O.R. = 4.4, p < 0.002 O.R. = 1.23, p = 0.44
Gross RD et al. The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:559-65
Can we prevent exacerbations with aspiration precautions,
swallowing training, or dietary modification?
Etiology of Exacerbations of COPD
• Obaji A, Sethi S. Drugs and Aging. 2001;18:1-11
e.g., air pollution. climate change, noncompliance,etc.
Bacteria
Bacteria and virus
Virus
Non-infectious
Antibiotics
Zpak is a simple prescription to write because it comes in a self-explanatory packet.--- Indiana School of Optometry
Erythromcycin decreases frequency, severity and time to first exacerbation
Seemungal TA, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139-47
•N = 109 pts
•Erythromycin 250mg bid
•36% reduction in exacerbations
Clinical trial of doxycycline in COPD flares treated with corticosteroids
• No difference in 30 day outcomes• Improved efficacy at day 10
Daniels JM, et. al.. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181:150-7
Impaired macrophage clearance of bacteria in COPD reversed with sulforaphane
0
50
100
150
200
250
Vehicle Sulforaphane
% In
ocul
ated
CFU
s P1P2P3P4P5P6P7P8P9 0
50
100
150
200
250
Vehicle Sulforaphane%
Inoc
ulat
ed C
FUs P6
P7P8P9P10P11P12P13P14
PA NTHI
*
*
Courtesy of C. Harvey, S. Biswal
Key Messages
• Recurrent hospital admissions are a major lever point for improving COPD care
• The future probably lies with real-world studies of combined therapies
• Both administrative and pharmacological strategies need to be explored conjointly
Thank you!